TSG101 exposure on the surface of HIV-1 infected cells: Implications for monoclonal antibody therapy for HIV/AIDS

American Journal of Translational Research

Volumn 2, Issue 4, 2010, Pages 368-380

  Diaz, Leyla ^a   Mao, Hanwen ^a   Zhou, Yu ^b   Kohli, Manu ^a   Cassella, Josephine ^a   Santos, David ^a   Fesseha, Zena ^a   Weng, Ke ^a   Chen, Hanson ^a   Bamba, Douty ^a   Marks, James D ^b   Goldblatt, Michael ^a   Kinch, Michael ^a  

^a Functional Genetics Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CB8 2; HIV; HIV AIDS therapy; Monoclonal antibody; TSG101

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CB8 2; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CELL SURFACE; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENCY; DRUG TARGETING; HOST; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIFE CYCLE; NONHUMAN; OUTER MEMBRANE; VIRUS INHIBITION; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77957354608     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Shafer RW and Schapiro JM. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. Aids Reviews 2008; 10: 67-84.
2. Malta M, Strathdee SA, Magnanini MMF and Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction 2008; 103: 1242-1257.
3. Ines SM, Moralejo L, Marcos M, Fuertes A and Luna G. Adherence to highly active antiretroviral therapy in HIV-infected inmates. Current Hiv Research 2008; 6: 164-170.
4. Bennett DE, Bertagnolio S, Sutherland D and Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antiviral Therapy 2008; 13: 1-13.
5. Tang JW and Pillay D. Transmission of HIV-1 drug resistance. Journal of Clinical Virology 2004; 30: 1-10.
6. Hughes A and Nelson M. HIV entry: new insights and implications for patient management. Current Opinion in Infectious Diseases 2009; 22: 35-42.
7. Wu XS, Lee VC, Chevalier E and Hwang ST. Chemokine Receptors as Targets for Cancer Therapy. Current Pharmaceutical Design 2009; 15: 742-757.
8. Hunt JS and Romanelli F. Maraviroc, a CCR5 Coreceptor Antagonist That Blocks Entry of Human Immunodeficiency Virus Type 1. Pharmacotherapy 2009; 29: 295-304.
9. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, Xavier RJ, Lieberman J and Elledge SJ. Identification of host proteins required for HIV infection through a functional genomic screen. Science 2008; 319: 921-926.
10. Konig R, Zhou YY, Elleder D, Diamond TL, Bonamy GMC, Irelan JT, Chiang CY, Tu BP, De Jesus PD, Lilley CE, Seidel S, Opaluch AM, Caldwell JS, Weitzman MD, Kuhen KL, Bandyopadhyay S, Ideker T, Orth AP, Miraglia LJ, Bushman FD, Young JA and Chanda SK. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 2008; 135: 49-60.
11. Calistri A, Salata C, Parolin C and Palu G. Role of multivesicular bodies and their components in the egress of enveloped RNA viruses. Reviews in Medical Virology 2009; 19: 31-45.
12. Smith GA and Enquist LW. Break ins and break outs: Viral interactions with the cytoskeleton of mammalian cells. Annual Review of Cell and Developmental Biology 2002; 18: 135-161.
13. Dohner K and Sodeik B. The role of the cytoskeleton during viral infection. Membrane Trafficking in Viral Replication 2004; 285: 67-108.
14. Lehmann-Che J and Saib A. Early stages of HIV replication: How to hijack cellular functions for a successful infection. Aids Reviews 2004; 6: 199-207.
15. Li L and Cohen SN. Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 1996; 85: 319-329.
16. Carter CA. Tsg101: HIV-1's ticket to ride. Trends in Microbiology 2002; 10: PII S0966-0842X (0902)02350-B.
17. Martin-Serrano J, Zang T and Bieniasz PD. Role of ESCRT-I in retroviral budding. J Virol 2003; 77: 4794-4804.
18. Demirov DG, Ono A, Orenstein JM and Freed EO. Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function. Proc Natl Acad Sci U S A 2002; 99: 955-960.
19. Martin-Serrano J, Zang T and Bieniasz PD. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat Med 2001; 7: 1313-1319.
20. Garrus JE, von Schwedler UK, Pornillos OW, Morham SG, Zavitz KH, Wang HE, Wettstein DA, Stray KM, Cote M, Rich RL, Myszka DG and Sundquist WI. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 2001; 107: 55-65.
21. Bache KG, Slagsvold T, Cabezas A, Rosendal KR, Raiborg C and Stenmark H. The growthregulatory protein HCRP1/hVps37A is a subunit of mammalian ESCRT-I and mediates receptor down-regulation. Mol Biol Cell 2004; 15: 4337-4346.
22. Goff A, Ehrlich LS, Cohen SN and Carter CA. Tsg101 control of human immunodeficiency virus type 1 Gag trafficking and release. J Virol 2003; 77: 9173-9182.
23. Pornillos O, Alam SL, Davis DR and Sundquist WI. Structure of the Tsg101 UEV domain in complex with the PTAP motif of the HIV-1 p6 protein. Nat Struct Biol 2002; 9: 812-817.
24. VerPlank L, Bouamr F, LaGrassa TJ, Agresta B, Kikonyogo A, Leis J and Carter CA. Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55 (Gag). Proc Natl Acad Sci U S A 2001; 98: 7724-7729.
25. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD and Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991; 222: 581-597.
26. Razai A, Garcia-Rodriguez C, Lou J, Geren IN, Forsyth CM, Robles Y, Tsai R, Smith TJ, Smith LA, Siegel RW, Feldhaus M and Marks JD. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol 2005; 351: 158-169.
27. Zhou Y, Drummond DC, Zou H, Hayes ME, Adams GP, Kirpotin DB and Marks JD. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol 2007; 371: 934-947.
28. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A and Martin MA. PRODUCTION OF ACQUIRED IMMUNODEFICIENCY SYNDROMEASSOCIATED RETROVIRUS IN HUMAN AND NONHUMAN CELLS TRANSFECTED WITH AN INFECTIOUS MOLECULAR CLONE. Journal of Virology 1986; 59: 284-291.
29. Chen MS, Singh MK, Balachandran R and Gupta P. Isolation and characterization of two divergent infectious molecular clones of HIV type 1 longitudinally obtained from a seropositive patient by a progressive amplification procedure. Aids Research and Human Retroviruses 1997; 13: 743-750.
30. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Titus D, Yang T, Teppler H, Squires KE, Deutsch PJ and Emini EA. IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS. Nature 1995; 374: 569-571.
31. Panchal RG, Ruthel G, Kenny TA, Kallstrom GH, Lane D, Badie SS, Li L, Bavari S and Aman MJ. In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc Natl Acad Sci U S A 2003; 100: 15936-15941.
32. Sheets MD, Amersdorfer P, Finnern R, Sargent P, Lindquist E, Schier R, Hemingsen G, Wong C, Gerhart JC and Marks JD. Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human singlechain antibodies to protein antigens. Proc Natl Acad Sci U S A 1998; 95: 6157-6162.
33. Huie MA, Cheung MC, Muench MO, Becerril B, Kan YW and Marks JD. Antibodies to human fetal erythroid cells from a nonimmune phage antibody library. Proc Natl Acad Sci U S A 2001; 98: 2682-2687.
34. O'Connell D, Becerril B, Roy-Burman A, Daws M and Marks JD. Phage versus phagemid libraries for generation of human monoclonal antibodies. J Mol Biol 2002; 321: 49-56.
35. Welsch S, Habermann A, Jager S, Muller B, Krijnse-Locker J and Krausslich HG. Ultrastructural analysis of ESCRT proteins suggests a role for endosome-associated tubular-vesicular membranes in ESCRT function. Traffic 2006; 7: 1551-1566.
36. Balasubramanian K, Mirnikjoo B and Schroit AJ. Regulated externalization of phosphatidylserine at the cell surface: implications for apoptosis. J Biol Chem 2007; 282: 18357-18364.
37. Soares MM, King SW and Thorpe PE. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nature Medicine 2008; 14: 1357-1362.
38. Japour AJ, Mayers DL, Johnson VA, Kuritzkes DR, Beckett LA, Arduino JM, Lane J, Black RJ, Reichelderfer PS, Daquila RT, Crumpacker CS, Balfour H, Erice A, Coombs R, Katzenstein D, Lathey J, Richman D, McIntosh K, Rangan S, Reichman R, Scott W, Ussery M, Abrams L, McCutchan F, Burke D, Gardner L, Roberts C, Chung R, Hicks C, Shellie E, Fowler A, Merritt L, Fujimurajustice M, Ruiz N, Wagner K and Gail M. STANDARDIZED PERIPHERAL-BLOOD MONONUCLEAR CELLCULTURE ASSAY FOR DETERMINATION OF DRUG SUSCEPTIBILITIES OF CLINICAL HUMANIMMUNODEFICIENCY- VIRUS TYPE-1 ISOLATES. Antimicrobial Agents and Chemotherapy 1993; 37: 1095-1101.
39. Krowicka H, Robinson JE, Clark R, Hager S, Broyles S and Pincus SH. Use of tissue culture cell lines to evaluate HIV antiviral resistance. Aids Research and Human Retroviruses 2008; 24: 956-966.
40. Bashirova AA, Bleiber G, Qi Y, Hutcheson H, Yamashita T, Johnson RC, Cheng J, Alter G, Goedert JJ, Buchbinder S, Hoots K, Vlahov D, May M, Maldarelli F, Jacobson L, O'Brien SJ, Telenti A and Carrington M. Consistent effects of TSG101 genetic variability on multiple outcomes of exposure to human immunodeficiency virus type 1. Journal of Virology 2006; 80: 6757-6763.
41. Zhu F, Zhou ZH and Liao YH. The reninangiotensin system and therapeutic vaccines for hypertension. Current Opinion in Investigational Drugs 2008; 9: 286-294.
42. Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, Ignatenko S, Volk HD, Stocker H, Muller P, Jennings GT, Wagner F and Bachmann MF. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008; 371: 821-827.
43. Miller SA, Accardi JR and Onge ELS. Angiotensin II vaccine: a novel approach in the treatment of hypertension. Expert Opinion on Biological Therapy 2008; 8: 1669-1673.